Composition, form of production and packaging
Spray nasal in the form of a transparent, colorless liquid.
100 ml
neomycin sulfate 1 g (650,000 IU)
polymyxin B sulfate 1 000 000 units
dexamethasone sodium metasulfobenzoate 25 mg
phenylephrine hydrochloride 250 mg
Auxiliary substances: methylparahydroxybenzoate - 100 mg, lithium chloride 340 mg, citric acid 280 mg, lithium hydroxide 100 mg, macrogol 400-5 g, polysorbate 80-200 mg, purified water up to 100 ml.
15 ml - polyethylene bottles with a sprayer (1) - packs cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2012.
PHARMACHOLOGIC EFFECT
Combined preparation for topical application in otorhinolaryngology. The therapeutic effect of Polidex's preparation with phenylephrine is due to the anti-inflammatory effect of dexamethasone on the nasal mucosa, the vasoconstrictive effect of phenylephrine and the antibacterial action of antibiotics of neomycin and polymyxin B. When combined with these antibiotics, the spectrum of antibacterial action extends to the majority of Gram-positive and Gram-negative microorganisms causing infectious and inflammatory diseases of the nasal cavity and paranasal sinuses.
PHARMACOKINETICS
Studies of the pharmacokinetics of the Polidex preparation with phenylephrine have not been carried out due to low systemic absorption.
INDICATIONS
Inflammatory and infectious diseases of the nasal cavity, pharynx, paranasal sinuses:
acute and chronic rhinitis;
- Acute and chronic rhinopharyngitis;
- sinusites.
DOSING MODE
Adults are prescribed for 1 injection 3-5 times / day in each nostril for 5-10 days.
Children aged 2.5 to 15 years - 1 injection 3 times / day in each nostril for 5-10 days.
SIDE EFFECT
Allergic reactions: rarely skin manifestations.
CONTRAINDICATIONS
- Suspicion of a closed-angle glaucoma;
- simultaneous use of MAO inhibitors;
- kidney disease, accompanied by albuminuria;
- Pregnancy;
- lactation (breastfeeding);
- Children's age up to 2.5 years;
- Hypersensitivity to the components of the drug.
PREGNANCY AND LACTATION
The preparation Polidexa with phenylephrine is contraindicated for use in pregnancy and lactation (breast-feeding).
APPLICATION FOR FUNCTIONS OF THE LIVER
Contraindicated use of the drug in diseases of the kidneys, accompanied by albuminuria.
The drug is not prescribed for patients with renal insufficiency.
APPLICATION FOR CHILDREN
Contraindicated in childhood to 2.5 years. Children aged 2.5 to 15 years are prescribed 1 injection 3 times / day in each nostril for 5-10 days.
SPECIAL INSTRUCTIONS
The drug is not prescribed for patients with renal insufficiency.
Do not use to wash the paranasal sinuses.
With caution apply the drug in patients with arterial hypertension, ischemic heart disease, hyperthyroidism.
It should be borne in mind that the drug contains components that can give a positive result in the conduct of doping control in athletes.
OVERDOSE
Due to the low degree of absorption in the systemic blood flow, an overdose is unlikely.
DRUG INTERACTION
Drug interaction is due to the content of phenylephrine. With the simultaneous use of guanethidine and drugs of this group, the hypertensive effect of phenylephrine is enhanced and, due to a decrease in sympathetic tone with guanethidine, a long mydriasis is possible. If this combination can not be avoided, then a doctor's observation is necessary.
TERMS OF RELEASE FROM PHARMACY
The drug is released by prescription.
TERMS AND CONDITIONS OF STORAGE
List B. The drug should be stored out of reach of children at a temperature of no higher than 25 В° C. Shelf life - 3 years.